Inhaled Formoterol Evaluated for Hypoglycemia in T1D

Inhaled Formoterol Evaluated for Hypoglycemia in T1D
Inhaled Formoterol Evaluated for Hypoglycemia in T1D

Use of β-2 adrenergic receptor (AR) agonists have been linked to a reduction in nocturnal hypoglycemia, but the efficacy of long-acting inhaled β-2 agonists for the treatment or prevention of hypoglycemia is unknown. Research in Diabetes Care describes a study in which seven patients with type 1 diabetes and seven healthy control subjects received inhaled formoterol 48mcg or placebo during a hyperinsulinemic-hypoglycemic clamp study to determine its efficacy in antagonizing the effect of insulin. In a second study, five subjects with type 1 diabetes received inhaled formoterol to evaluate its efficacy as a preventive treatment for insulin-induced hypoglycemia.

In the first study, inhaled formoterol reduced the glucose infusion rate required to maintain plasma glucose at target levels by 45–50% vs. placebo (P<0.05). No significant effect was seen on glucagon, epinephrine, cortisol, or growth hormone release. In participants with type 1 diabetes, glucose levels dropped to 58 ± 5mg/dL one hour after increasing basal insulin delivery twofold, whereas hypoglycemia was prevented by inhaled formoterol (P<0.001).

Inhalation of formoterol could be helpful in the prevention or treatment of acute hypoglycemia in patients with type 1 diabetes, but additional studies are needed to assess its safety and efficacy. Currently formoterol is used in the treatment and maintenance of asthma and chronic obstructive pulmonary disease (COPD).

READ FULL ARTICLE From Diabetesjournals

Loading links....